Home  |  Media  |  Papers & Publications  |  Mailing List  |  Comments  |  Contact Me                                                                          Bookmark This Page
Dr. Steven Treon
Dr. Treon is listed by US News & World Report as being in the top 1% of all doctors in the United States for his specialty.


Please visit our main program website: Bing Center for Waldenstrom's Macroglobulinemia. This site contains information on the latest treatment recommendations, abstracts, news and events, current and pending clinical trials and participating institutions, basic research, and publications, as well as photos and brief bios of the Bing Center staff.


WM Workshops: Starting with the first International Workshop for WM in Washington DC in Sept. 2000, worshops have been held bi-annually, the most recent in August 2014 in London, UK. These workshops provide a venue for the WM scientific community to collaborate and share their latest research with the goal of advancing the knowledge of the genetic basis and pathogenesis of WM, and the development of theraputics for this malignancy. To learn more, please visit our WM Workshop Website.


Patient/Physician Summits: Starting with the first summit in Boston in November, 2001, these conferences have provided a valuable opportunity for patients, their families and caregivers to meet face-to-face with the leaders of the WM scientific community. They can learn the latest developments in the research and treatment of WM, and also participate in working sessions and panel discussions. To learn more, please visit our WM Summit Website.


WM Clinical Trials Group: To find a WM specialist in your area, including information on clinical trials involving WM, please visit our WM Clinical Trials Group Website.

MYD88 L265P is a commonly recurring mutation in patients with Waldenström’s macroglobulinemia that can be useful in differentiating Waldenström’s macroglobulinemia and non-IgM LPL from B-cell disorders that have some of the same features. Click the graphic to download this groundbreaking NEJM publication.


Dedicated to the Discovery of the Cause and Cure of Waldenstrom's Macroglobulinemia

Dr. Steven Treon is the Director of the Bing Center for Waldenström's Macroglobulinemia and an Attending Physician for the Department of Medical Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital in Boston, Massachusetts. He is also an Associate Professor of Medicine at Harvard Medical School in Boston, and is the Chair of the Waldenström's Macroglobulinemia Clinical Trials Group.

Dr. Treon received a medical degree with honors from the Boston University School of Medicine, and a master’s degree in biochemistry and a doctorate of philosophy in tumor immunology from the graduate school at Boston University Medical Center. Dr Treon completed an internship and residency in internal medicine at Boston University Medical Center. He also completed a clinical fellowship in hematology and oncology at the Massachusetts General Hospital and a research fellowship at the Dana-Farber Cancer Institute and Harvard Medical School. He received certification from the American Board of Internal Medicine (ABIM) in Internal Medicine and Medical Oncology, and continues to maintain his ABIM certification in Medical Oncology.

Dr. Treon’s research interests are focused on understanding the genetic basis and pathogenesis of Waldenström’s Macroglobulinemia (WM), and the development of targeted therapeutics for this malignancy. Using whole genome sequencing, the Treon laboratory discovered the highly prevalent MYD88 L265P and CXCR4 WHIM mutations in WM, permitting the development of diagnostic molecular testing and targeted treatments for WM. Signaling work performed in the Treon laboratory established the critical role of Bruton’s Tyrosine Kinase (BTK) as a key mediator of MYD88 signaling in WM cells. This discovery enabled the first ever breakthrough designation by the U.S. FDA for the accelerated approval of the BTK inhibitor ibrutinib for the treatment of WM. Dr. Treon served as the principal investigator of the pivotal trial that supported the regulatory approval of ibrutinib by the U.S. FDA and European Medicines Agency for the treatment of WM. He has also been the principal investigator for other clinical trials that resulted in the adoption of many novel therapeutics and combination therapies for the treatment of WM.

Dr. Treon has published over 250 original articles, reviews, reports, and book chapters that have appeared in many high impact journals and text books. He has been a keynote speaker and lecturer on the genomic basis, pathogenesis, clinical features, and treatment of WM at prestigious national congresses, international conferences, hospital grand rounds, tumor boards, regional medical society conferences, workshops, and patient meetings. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, European Society of Hematology, and the British Society of Hematology, and has given “Meet the Professor”, Educational Session, as well as presentations on original research at the annual meetings of these associations. Dr. Treon is also the principal organizer of the International Workshops on WM which have served as the principal forum for the exchange of novel scientific and clinical data on WM. He has been a mentor to physicians and scientists at the Bing Center for WM, and is also a regular lecturer at Harvard Medical School and its affiliated hospitals where he teaches medical students, interns, residents and fellows on the topic of plasma cell malignancies.

For his clinical and research efforts, Dr. Treon has received awards from various organizations including an ASCO Young Investigator Award, the Robert A. Kyle Award, the Jan Gosta Waldenstrom Lifetime Achievement Award, the Laurie Strauss Leukemia Society Outstanding Cancer Investigator Award, designation as “America’s Top Doctor” by U.S. News and World Report, and the “One-Hundred Award” from the Massachusetts General Hospital. In 2011, and 2013, Dr. Treon’s research work received “Best of ASH” designations at the Annual Meeting of the American Society of Hematology.

Featured News Items

May 1-3, 2015: IWMF Ed Forum, Dallas, TX - Genomic-Based Treatment Advances in WM

February, 2015: Many WM patients and caregivers have had questions about the pathway that led to the FDA approval of Imbruvica for WM. Please see the following videos of Dr Treon’s interviews on this historic approval which I hope would be able to answer many of your questions. Please Note: These interviews should not be considered an endorsement of Imbruvica or Pharmacyclics Inc. You should consult with your doctor regarding appropriate treatments. For more information, please visit http://www.prnewswire.com/news-releases/us-fda-approves-imbruvica-ibrutinib-for-treatment-of-waldenstroms-macroglobulinemia-wm-300027914.html

August, 2014, London, UK: The 8th International Workshop for Waldenstrom's Macroglobulinemia and Symposium on Advances in Multiple Myeloma was held from August 13-17, 2014 at the Park Plaza Westminster Hotel, in beautiful historic London, UK. The workshop was attended by over 200 scientists and research staff, representing 20 countries. IWWM-8 included 12 sessions with 50 technical presentations, 8 "Great Debates" (4-MM, 4-WM), 38 poster presentations, including a 2-hour poster session with short oral presentations of accepted posters, a special Saturday luncheon lecture by Dr. Shirley D'Sa, and 4 "Task Force" discussions on various topics in WM. Opening & Closing ceremonies included the awarding of the 2014 Robert Kyle award to Dr. Roger Owen, and the 2014 Waldenstrom Award was shared between Drs. Enrica Morra and Morie Gertz.